In This Article:
Louvain-La-Neuve, Belgium, March 04, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a term sheet with Apollo Hospitals Enterprise Limited (AHEL) for the supply of one Proteus®ONE1 compact proton therapy solution plus a second one in option. Apollo will therefore expand access to proton therapy in India. The term sheet was signed in the presence of Her Royal Highness Princess Astrid of Belgium.
These systems expand upon the existing collaboration between the two partners, with AHEL having previously selected an IBA Proteus®PLUS1 system in 2013 and introduced the first proton beam therapy in India. AHEL expects to start treating patients with the Proteus®ONE systems by 2028.
Proteus®ONE is the market leading compact proton therapy system, which is upgradable over time to continue providing the latest technology to IBA users. The systems will include DynamicARC®2 beam delivery capabilities when regulatory clearance is granted.
The typical end-user price for a Proteus®ONE system with a multi-year maintenance contract ranges between EUR 35 and 45 million.
Olivier Legrain, Chief Executive Officer of IBA, commented: “These contracts expand upon the close relationship we have built for more than a decade with Apollo Hospitals. Having an existing customer reaffirm their confidence in our solutions demonstrates not only the reliability and superiority of the IBA portfolio but also highlights the level of excellence of the services we deliver. We look forward to further strengthening our relationship with Apollo as we enable more patients in India to gain access to this life-saving treatment modality.”
Dr. Prathap C Reddy, Founder and Chairman of Apollo Hospitals Enterprise Ltd, added: “Our relentless pursuit of excellence in healthcare drives us to bring the most advanced medical technologies to India. In 2019, Apollo commissioned the first proton therapy system in India and till date we have treated over 2000 patients from over 147 countries. We are excited to partner with IBA again as we expand our proton therapy treatment capacity. The addition of Proteus®ONE further cements our position as a global leader in proton beam therapy treatments, enabling us to deliver superior clinical outcomes and improve the quality of life for cancer patients in India and worldwide.”
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be the most advanced form of radiation therapy available today, industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.